Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA Panel May Withdraw Avastin Indication

By Drug Discovery Trends Editor | July 20, 2010

WASHINGTON (AP) – Federal health advisers will vote today on whether to withdraw regulatory approval of the Roche drug Avastin for breast cancer treatment after the drug showed disappointing results in recent studies.

The Food and Drug Administration in 2008 approved Avastin for breast cancer patients based on a trial showing it significantly lengthened the amount of time until the disease worsened. As a condition of approval, Roche was required to conduct follow-up studies to further demonstrate the benefits of adding Avastin to conventional chemotherapy.

The FDA is asking a panel of experts to review two new Avastin studies in which the drug failed to show a survival benefit. Additionally, the follow-up studies did not show the same degree of delay in cancer progression as earlier studies.

The panel of cancer experts will vote on whether to withdraw Avastin’s approval in breast cancer. Avastin is also approved for colon, lung, kidney and brain cancer.

Panelists will be asked to weigh the potential benefits of the drug against its side effects, which include high blood pressure, fatigue and abnormal white blood cell levels.

The FDA is not required to follow its panel’s advice, though it often does.

Avastin was Roche’s top-selling cancer treatment last year with global sales of $5.9 billion.

Breast cancer is the second most common cause of cancer death among U.S. women, according to the Centers for Disease Control. Last year more than 40,000 deaths in the U.S. were attributed to the disease.

Date: July 20, 2010
Source: Associated Press

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50